RedHill Biopharma (RDHL) Cash from Operations (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Cash from Operations data on file, last reported at 2421000.0 in Q4 2022.

• Cash from Operations for Q4 2022 came in at 2421000.0, up 83.71% year-over-year; the trailing twelve-month figure through Dec 2022 was 29185000.0 (up 55.13% YoY), and the FY2025 annual result was 7191000.0, up 19.52% from the prior year.
• Cash from Operations grew to 2421000.0 in Q4 2022 per RDHL's latest filing, from 6028000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 2421000.0 in Q4 2022 and troughed at 19025000.0 in Q3 2021.
• A 5-year average of 10848650.0 and a median of 9974500.0 in 2018 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2021 and 2022: Cash from Operations plunged 107.45% in 2021, then surged 83.71% in 2022.
• A 5-year view of Cash from Operations shows it stood at 8194000.0 in 2018, then tumbled by 69.26% to 13869000.0 in 2019, then increased by 8.39% to 12705000.0 in 2020, then decreased by 16.95% to 14859000.0 in 2021, then surged by 83.71% to 2421000.0 in 2022.
• Business Quant data shows RDHL's Cash from Operations at 2421000.0 in Q4 2022, 6028000.0 in Q3 2022, and 16581000.0 in Q2 2022.